|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Erez N, Glanz S, Raz Y, Avivi C and
Barshack I: Cancer associated fibroblasts express pro-inflammatory
factors in human breast and ovarian tumors. Biochem Biophys Res
Commun. 437:397–402. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Del Prete A, Allavena P, Santoro G,
Fumarulo R, Corsi MM and Mantovani A: Molecular pathways in
cancer-related inflammation. Biochem Med. 21:264–275. 2011.
View Article : Google Scholar
|
|
6
|
Chen R, Yu Z, Zhang H, Ding J and Chen B:
Primary malignant lymphoma of the uterus and broad ligament: A case
report and review of literature. Onco Targets Ther. 8:265–268.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Polanska UM and Orimo A:
Carcinoma-associated fibroblasts: Non-neoplastic tumour-promoting
mesenchymal cells. J Cell Physiol. 228:1651–1657. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huynh PT, Beswick EJ, Coronado YA, Johnson
P, O'Connell MR, Watts T, Singh P, Qiu S, Morris K, Powell DW and
Pinchuk IV: CD90+ stromal cells are the major source of IL-6, which
supports cancer stem-like cells and inflammation in colorectal
cancer. Int J Cancer. 138:1971–1981. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Johansson AC, Ansell A, Jerhammar F, Lindh
MB, Grénman R, Munck-Wikland E, Östman A and Roberg K:
Cancer-associated fibroblasts induce matrix
metalloproteinase-mediated cetuximab resistance in head and neck
squamous cell carcinoma cells. Mol Cancer Res. 10:1158–1168. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yeung Au CL, Co NN, Tsuruga T, Yeung TL,
Kwan SY, Leung CS, Li Y, Lu ES, Kwan K, Wong KK, et al: Exosomal
transfer of stroma-derived miR21 confers paclitaxel resistance in
ovarian cancer cells through targeting APAF1. Nat Commun.
7:111502016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Abubaker K, Luwor RB, Escalona R, McNally
O, Quinn MA, Thompson EW, Findlay JK and Ahmed N: Targeted
disruption of the JAK2/STAT3 pathway in combination with systemic
administration of paclitaxel inhibits the priming of ovarian cancer
stem cells leading to a reduced tumor burden. Front Oncol.
4:752014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Colomiere M, Ward AC, Riley C, Trenerry
MK, Cameron-Smith D, Findlay J, Ackland L and Ahmed N: Cross talk
of signals between EGFR and IL-6R through JAK2/STAT3 mediate
epithelial-mesenchymal transition in ovarian carcinomas. Br J
Cancer. 100:134–144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu J, Zhang J, Shen B, Yin K, Xu J, Gao W
and Zhang L: Long noncoding RNA lncTCF7, induced by IL-6/STAT3
transactivation, promotes hepatocellular carcinoma aggressiveness
through epithelial-mesenchymal transition. J Exp Clin Cancer Res.
34:1162015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fischer KR, Durrans A, Lee S, Sheng J, Li
F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al:
Epithelial-to-mesenchymal transition is not required for lung
metastasis but contributes to chemoresistance. Nature. 527:472–476.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zheng X, Carstens JL, Kim J, Scheible M,
Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R:
Epithelial-to-mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Nature.
527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nagasaki T, Hara M, Nakanishi H, Takahashi
H, Sato M and Takeyama H: Interleukin-6 released by colon
cancer-associated fibroblasts is critical for tumour angiogenesis:
Anti-interleukin-6 receptor antibody suppressed angiogenesis and
inhibited tumour-stroma interaction. Br J Cancer. 110:469–478.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takai M, Terai Y, Kawaguchi H, Ashihara K,
Fujiwara S, Tanaka T, Tsunetoh S, Tanaka Y, Sasaki H, Kanemura M,
et al: The EMT (epithelial-mesenchymal-transition)-related protein
expression indicates the metastatic status and prognosis in
patients with ovarian cancer. J Ovarian Res. 7:762014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang X, Hou Y, Yang G, Wang X, Tang S, Du
YE, Yang L, Yu T, Zhang H, Zhou M, et al: Stromal miR-200s
contribute to breast cancer cell invasion through CAF activation
and ECM remodeling. Cell Death Differ. 23:132–145. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Fan Q, Li J, Song J and Gu Y:
MiR-124 down-regulation is critical for cancer associated
fibroblasts-enhanced tumor growth of oral carcinoma. Exp Cell Res.
351:100–108. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dobrzycka B, Mackowiak-Matejczyk B,
Terlikowska KM, Kulesza-Bronczyk B, Kinalski M and Terlikowski SJ:
Serum levels of IL-6, IL-8 and CRP as prognostic factors in
epithelial ovarian cancer. Eur Cytokine Netw. 24:106–113.
2013.PubMed/NCBI
|
|
21
|
Lo CW, Chen MW, Hsiao M, Wang S, Chen CA,
Hsiao SM, Chang JS, Lai TC, Rose-John S, Kuo ML and Wei LH: IL-6
trans-signaling in formation and progression of malignant ascites
in ovarian cancer. Cancer Res. 71:424–434. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Osuala KO, Sameni M, Shah S, Aggarwal N,
Simonait ML, Franco OE, Hong Y, Hayward SW, Behbod F, Mattingly RR
and Sloane BF: Il-6 signaling between ductal carcinoma in situ
cells and carcinoma-associated fibroblasts mediates tumor cell
growth and migration. BMC Cancer. 15:5842015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X,
Li J, Li C, Yan M, Zhu Z, et al: IL-6 secreted by cancer-associated
fibroblasts promotes epithelial-mesenchymal transition and
metastasis of gastric cancer via JAK2/STAT3 signaling pathway.
Oncotarget. 8:20741–20750. 2017.PubMed/NCBI
|
|
24
|
Wang Y, Li L, Guo X, Jin X, Sun W, Zhang X
and Xu RC: Interleukin-6 signaling regulates anchorage-independent
growth, proliferation, adhesion and invasion in human ovarian
cancer cells. Cytokine. 59:228–236. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jin S, Mutvei AP, Chivukula IV, Andersson
ER, Ramsköld D, Sandberg R, Lee KL, Kronqvist P, Mamaeva V, Ostling
P, et al: Non-canonical Notch signaling activates IL-6/JAK/STAT
signaling in breast tumor cells and is controlled by p53 and
IKKα/IKKβ. Oncogene. 32:4892–4902. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Subramaniam KS, Omar IS, Kwong SC, Mohamed
Z, Woo YL, Adenan Mat NA and Chung I: Cancer-associated fibroblasts
promote endometrial cancer growth via activation of
interleukin-6/STAT-3/c-Myc pathway. Am J Cancer Res. 6:200–213.
2016.PubMed/NCBI
|
|
27
|
Xiao J, Gong Y, Chen Y, Yu D, Wang X,
Zhang X, Dou Y, Liu D, Cheng G, Lu S, et al: IL-6 promotes
epithelial-to-mesenchymal transition of human peritoneal
mesothelial cells possibly through JAK2/STAT3 signaling pathway. Am
J Physiol Renal Physiol. 313:F310–F318. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shintani Y, Fujiwara A, Kimura T, Kawamura
T, Funaki S, Minami M and Okumura M: IL-6 secreted from
cancer-associated fibroblasts mediates chemoresistance in NSCLC by
increasing epithelial-mesenchymal transition signaling. J Thorac
Oncol. 11:1482–1492. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yan H, Guo BY and Zhang S:
Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis
in ovarian cancer cells by promoting STAT3 signaling. Biochem
Biophys Res Commun. 470:947–954. 2016. View Article : Google Scholar : PubMed/NCBI
|
